ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 529

The Relationship Between Promis and CDAI Scores, Disease Duration, Age and Gender in Patients with Rheumatoid Arthritis

Alicia Lieberman1, Judith Baumhauer2, Chris Dasilva2 and Allen P. Anandarajah3, 1Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, 2Orthopedic surgery, University of Rochester Medical Center, Rochester, NY, 3Dept of Rheumatology, Univ of Rochester Medical Ctr, Rochester, NY

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Disease Activity, pain, physical function and rheumatoid arthritis (RA), PROMIS

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:   PROMIS (Patient-Reported Outcomes Measurement Information System) is a self-reported and parent-reported measure of global, physical, mental, and social health for the general population and those living with chronic conditions. Recent studies have demonstrated preliminary evidence of reliability and construct validity of PROMIS to assess Rheumatoid arthritis (RA) symptoms, impact, and feasibility of use in clinical care. The performance of PROMIS domains in subgroups and relationship to other disease activity scores in RA however has not been established. The aim of our study was to compare Clinical Disease Activity Index (CDAI) scores with PROMIS scores overall as well as stratify for disease duration, age and gender in RA patients.

Methods:  This was a single center retrospective study. We analyzed the records of all RA patients seen over the last 6 months at the RA clinic in the University of Rochester. We compared the CDAI scores when available to the physical function (PF), pain interference (PI) and depression (Dep) PROMIS scores. We also calculated the effect of disease duration, age and gender on PROMIS PF, PI and Dep domains. Additionally, we compared the PROMIS scores of RA patients to a cohort of orthopedic patients with foot and ankle disease.

Results:  We identified a total of 144 patients with RA with a median age of 59 and median disease duration of 10 years. There were 108 females and 36 males. CDAI scores were available for 45 patients. The mean CDAI score was 8.2 (median 2.5). PF decreased while PI and depression worsened with increase in CDAI scores (see Table 1). Scores for Dep (52.1), PF (40.0) and PI (61.6) were also worse for those with disease duration of less than 1 year since diagnosis of RA (median 52.1 and 61.6) compared with those with 1-5 years, 6-10 years and more than 11 years with RA (see Table 2). No significant difference was noted in PROMIS scores based on gender. Similarly, no difference was noted in PROMIS scores for the different age groups: those less 40 years, 40-50, 51-60 and those over 60 years. Surprisingly, no difference was noted in the PROMIS scores between the RA cohort when compared to all rheumatology patients (n=370) and a cohort of patients with foot and ankle disease (n=25,690).

Conclusion:   Physical function, Pain Interference and depression PROMIS scores are associated with disease activity in RA patients as measured by CDAI. PROMIS scores are also affected by disease duration but not age or gender among RA patients. PROMIS is a valuable tool in the assessment of RA patients.

  Remission Low disease Activity Moderate disease activity High disease activity
Physical Function 48.92 42.95 37.74 38.16
Pain 46.64 54.92 64.78 65.19
Mood 45.76 49.01 48.39 55.11

Table 1: relationship between CDAI and PROMIS scores

Disease Duration

Physical function

Pain

Mood

Less than 1 year

40.00

61.55

52.12

1-5 years

47.64

52.57

43.01

6-10 years

43.50

57.79

48.18

More than 11 years

41.77

55.98

48.80

Table 2: Effect of disease duration on PROMIS score in RA patients


Disclosure: A. Lieberman, None; J. Baumhauer, wright medical, Nextremity solutions, DJO, Cartiva, Ferring Pharma, 5; C. Dasilva, None; A. P. Anandarajah, None.

To cite this abstract in AMA style:

Lieberman A, Baumhauer J, Dasilva C, Anandarajah AP. The Relationship Between Promis and CDAI Scores, Disease Duration, Age and Gender in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/the-relationship-between-promis-and-cdai-scores-disease-duration-age-and-gender-in-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-relationship-between-promis-and-cdai-scores-disease-duration-age-and-gender-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology